FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to ... This cathepsin K inhibitor, which is currently in Phase III trials ...

Despite recent challenges, the company’s strong product portfolio and robust pipeline continue to position it favorably for future growth. This comprehensive analysis examines Eli Lilly’s ...

Eli Lilly and Company (NYSE:LLY), with a market capitalization of $771 billion, stands as a prominent player in the pharmaceuticals industry. The company has been making significant strides in the ...